Barber-Say Syndrome (BBRSAY) — Comprehensive Research Report

MONDO:0008853 | OMIM #209885 | Orphanet ORPHA:1231 | ICD-10 Q87.0 | SNOMED CT 408537003 | Gene: TWIST2 (HGNC:20670, NCBI Gene 117581, 2q37.3)

Important disambiguation up front

Barber-Say syndrome (BSS, this report) must not be confused with Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS), also called the SBBYS variant of Ohdo syndrome. Despite the overlapping eponym ("Say," "Barber"), SBBYSS is a distinct, unrelated disorder caused by KAT6B haploinsufficiency, featuring severe intellectual disability, blepharophimosis (narrow palpebral fissures — the opposite of BSS's macrostomia/ectropion pattern), and patellar anomalies. Several general search indices and even some clinical summaries conflate the two names. This report addresses only TWIST2-related Barber-Say syndrome. This is exactly the kind of named-entity confusion dismech's curation guidance warns about, and any future curation of this entry should not import KAT6B/SBBYSS content.

1. Disease Information

Barber-Say syndrome is an ultra-rare congenital malformation syndrome first delineated by Barber et al. in 1982 (Syndrome Identification VIII(1):6–9), describing a 3.5-year-old girl with "macrostomia, ectropion, atrophic skin, marked hypertrichosis, and growth retardation" (as summarized in later literature). It is now understood as an autosomal dominant disorder — virtually always arising de novo, occasionally transmitted by a mosaic parent — caused by recurrent heterozygous missense substitutions at a single codon (p.Glu75) in the basic DNA-binding domain of the bHLH transcription factor TWIST2 (Marchegiani et al. 2015, PMID:26119818).

Key identifiers: - OMIM: #209885 (phenotype), *607556 (TWIST2 gene) - Orphanet: ORPHA:1231 - MONDO: 0008853 - ICD-10: Q87.0 (congenital malformation syndromes predominantly affecting facial appearance) - SNOMED CT: 408537003 - Gene: TWIST2 / DERMO1, HGNC:20670, NCBI Gene 117581, chr2:238,848,032–238,910,534 (GRCh38), 2q37.3

Synonyms: none widely used beyond "Barber-Say syndrome" / "BBRSAY"; occasionally listed with the informal descriptive label "hypertrichosis-atrophic skin-ectropion-macrostomia syndrome."

Source basis: Information is derived almost entirely from aggregated individual case reports and small case series (fewer than 20–25 published probands as of the most recent literature identified in this search), plus one pivotal multi-family molecular genetics study (Marchegiani et al. 2015) that pooled 11 BSS-affected families with 7 ablepharon-macrostomia syndrome (AMS) families. There is no GeneReviews chapter for Barber-Say syndrome (none was found in this search), and no disease registry or EHR-aggregated cohort exists — this is a disease known only from the case-report literature, which should be reflected in any evidence_source: HUMAN_CLINICAL grading as individual-patient rather than population-level evidence.

2. Etiology

Disease causal factor: Purely genetic/molecular. BSS is caused by heterozygous, essentially always de novo, missense mutations in the basic domain of TWIST2, most recurrently p.Glu75Gln (E75Q) and less commonly p.Glu75Ala (E75A) (Marchegiani et al. 2015, PMID:26119818: "a lysine at TWIST2 residue 75 resulted in AMS, whereas a glutamine or alanine yielded BSS," with 9 of 11 BSS families carrying p.Glu75Gln and 2 carrying p.Glu75Ala).

Genetic risk factors: - The causal locus is TWIST2 itself; there is no known population-level susceptibility variant — this is a fully penetrant, single-gene, single-codon dominant disorder, not a complex/multifactorial trait. - Germline/parental mosaicism is the specific recurrence-risk factor identified in the literature: Marchegiani et al. 2015 report "three disease-transmitting fathers with mild AMS or BSS and variable skin pigmentation were mosaic for a TWIST2 mutation," and Singh et al. 2016 (PMID:27092433) document transmission of the p.E75Q mutation from a somatically/gonadally mosaic, mildly affected father to a severely affected daughter in an Indian family — establishing that an apparently unaffected or minimally affected parent can still confer significant recurrence risk via germline mosaicism, relevant for genetic counseling. - No modifier genes have been reported.

Environmental risk factors: None identified or plausible for a single-gene bHLH transcription-factor disorder; no association with parental age, teratogen exposure, or periconceptional factors was found in this search.

Protective factors: None described; not applicable to this class of fully penetrant dominant missense disorder.

Gene-environment interactions: None reported; not applicable.

3. Phenotypes

BSS phenotypes cluster into craniofacial/ocular, integumentary (the dominant and defining system), and lesser genitourinary/dental/auditory findings. Onset is congenital in all cases (present at birth); there is no reported postnatal-onset phenotype, and the facial gestalt and skin findings are typically described as static/non-progressive rather than degenerative, though the aged, redundant-skin appearance can be mistaken for a progeroid process.

Severity/progression: Facial and integumentary features are present at birth and are generally described as static rather than progressive; the main progression concern is secondary, acquired complications — corneal exposure and ulceration from chronic ectropion/lagophthalmos, which can worsen over time without surgical correction and represent the principal ophthalmologic threat to vision.

Quality-of-life impact: No formal EQ-5D/SF-36/QOL instrument data were found for this ultra-rare condition. Documented impacts described qualitatively in case reports and at least one patient-perspective publication (Küry et al./De Maria, "A Patient's View," PMID:28690482) include: disfigurement-related psychosocial burden, feeding difficulty related to macrostomia in infancy, need for repeated reconstructive surgeries (eyelid, oral commissure, craniofacial), and corneal/visual morbidity from exposure keratopathy. Cognitive/motor development is reported as normal in the majority of cases, a key point distinguishing BSS from many other multiple-congenital-anomaly syndromes and specifically from SBBYSS.

4. Genetic/Molecular Information

Causal gene: TWIST2 (OMIM *607556), HGNC:20670, chr2:238,848,032-238,910,534 (2q37.3).

Pathogenic variants (BSS-specific): - p.Glu75Gln (E75Q) — the recurrent, most common BSS allele (9/11 families in Marchegiani et al. 2015) - p.Glu75Ala (E75A) — the second recognized BSS allele (2/11 families) - Both fall within the basic domain of the bHLH protein — the DNA-contacting region — and were shown by ChIP-seq/EMSA-type analyses in the Marchegiani study to alter TWIST2's DNA-binding pattern: "All identified mutations fell in the basic domain of TWIST2 and altered the DNA-binding pattern of Flag-TWIST2 in HeLa cells," with the mutant proteins sharing only a fraction of their genomic binding peaks with wild-type TWIST2 and gaining new, non-wild-type binding sites.

Variant classification: These recurrent missense substitutions are classified pathogenic under ACMG/AMP criteria in the primary literature (recurrent de novo occurrence across unrelated families, functional evidence of altered DNA binding, precise genotype-phenotype correlation). No formal ClinVar aggregate statistics were retrieved in this search; curators should independently confirm current ClinVar classification for p.Glu75Gln/p.Glu75Ala before citing a specific pathogenicity tier.

Allele frequency: Not present in population databases (gnomAD/1000 Genomes/TOPMed) at meaningful frequency — consistent with a fully penetrant, severe, essentially always-de-novo dominant disorder; no specific gnomAD constraint metrics (e.g., pLI, missense Z-score) for TWIST2 were retrieved in this search and should be pulled directly from gnomAD if needed for curation.

Somatic vs. germline origin: Germline (constitutional), with the specific and clinically important caveat of parental somatic/germline mosaicism as the recurrence mechanism in familial transmission (see §2 and §9).

Functional consequences — the central mechanistic ambiguity: The literature explicitly frames the E75Q/E75A (BSS) and E75K (AMS) substitutions as producing both dominant-negative and gain-of-function (neomorphic) effects simultaneously, rather than a clean loss- or gain-of-function classification:

"The mutations are located in the basic domain of the protein, and molecular analyses suggested that the mutations alter the DNA-binding activity of TWIST2, leading to both dominant-negative and gain-of-function effects" (Marchegiani et al. 2015, PMID:26119818, as reported in secondary summaries of the primary text).

Mechanistically this is attributed to (a) partial loss of binding to TWIST2's normal E-box target sites (dominant-negative component) combined with (b) acquisition of binding to abnormal, non-wild-type genomic sites (neomorphic/gain-of-function component) — "a dominant-negative effect due to loss of binding to the normal contingent of TWIST2 DNA binding sites or a neomorphic mechanism due to binding of the mutant TWIST2 to extraneous promoter sites." This dual mechanism is the key curatorial subtlety: a GeneticContext.functional_impact_category of a single enum value (e.g., DOMINANT_NEGATIVE) would understate what the primary literature actually claims; curators should consider whether the schema's controlled vocabulary can capture both components or whether free text is needed alongside the closest enum value.

Modifier genes: None established.

Epigenetic information: No disease-specific DNA methylation/histone data for BSS were found. Note, however, that TWIST2 itself functions partly through chromatin remodeling in dermal fibroblast maturation more broadly (Twist2-driven chromatin remodeling in postnatal dermal fibroblasts, ScienceDirect/iScience-type source found in search) — this is basic TWIST2 developmental biology, not BSS-specific pathological epigenetic data, and should not be conflated with disease-causing epigenetic changes.

Chromosomal abnormalities: Not applicable to BSS itself (a single-gene point-mutation disorder). Note for differential/related-locus awareness: TWIST2 sits within the region implicated in 2q37 deletion syndrome, and TWIST2 has been "proposed as a candidate gene for 2q37 deletion syndrome due to its localization in the smallest deleted chromosome region" — this is a distinct, contiguous-gene-deletion condition and should not be merged with BSS in curation.

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors were identified in this search, consistent with BSS being a fully genetically determined, single-gene disorder with no reported gene-environment interaction. This section is not applicable beyond noting its inapplicability.

6. Mechanism / Pathophysiology

Causal chain (ordered, with inference flagged)

1. A de novo (or paternally/maternally transmitted-via-mosaicism) heterozygous missense substitution — most often p.Glu75Gln, less often p.Glu75Ala — arises in the basic DNA-binding domain of TWIST2, a basic helix-loop-helix (bHLH) transcription factor. (Demonstrated: recurrent mutation identification across 11 independent families, PMID:26119818.)
2. This alters the amino-acid sequence of the DNA-contacting basic domain, changing TWIST2's DNA-binding specificity: the mutant protein partially loses binding at wild-type TWIST2 target sites and gains binding at abnormal, non-wild-type genomic sites, as shown by comparative binding-peak analysis of mutant vs. wild-type TWIST2 in cell-based assays. (Demonstrated in vitro, PMID:26119818.)
3. This dual DNA-binding disruption leads downstream to a combined dominant-negative and neomorphic (gain-of-function) transcriptional effect on TWIST2's normal target gene network — rather than simple TWIST2 haploinsufficiency. (Inferred from binding data and genotype-phenotype correlation; direct downstream transcriptomic confirmation in human tissue is limited.)
4. TWIST2 is normally a heterodimeric partner (with E-box-binding partners such as the ubiquitous bHLH protein E12/TCF3) that, during embryogenesis, is highly expressed in craniofacial mesenchyme and chondrogenic/dermal precursor cells, where it inhibits terminal differentiation of mesenchymal lineages (myogenic, osteogenic) and directs dermal fibroblast and chondrogenic tissue development. (Established developmental biology of wild-type TWIST2; PMID:26119818 and general TWIST2 literature.)
5. Disrupted TWIST2 transcriptional output in these mesenchymal precursor populations leads to abnormal craniofacial mesenchymal and periocular (eyelid) tissue development, manifesting as underdevelopment of the eyelid anterior lamella (→ ectropion), abnormal maxillary/oral mesenchyme patterning (→ macrostomia), and abnormal nasal/auricular cartilage and soft-tissue development (→ bulbous nose, dysplastic ears). (Inferred from the tissue-expression pattern and the clinical phenotype; directly demonstrated in a zebrafish model, see below.)
6. In parallel, disrupted TWIST2 function in dermal fibroblast precursors impairs normal extracellular matrix (elastic fiber and collagen) deposition, producing the histologically documented thin epidermis, markedly reduced dermal elastic fibers, and hypocollagenosis. (Demonstrated histologically in patient skin biopsies; mechanistic link to TWIST2's fibroblast-differentiation role is inferred by analogy to TWIST2's known role in postnatal dermal fibroblast chromatin regulation, not directly shown in BSS patient fibroblast transcriptomics in the sources retrieved here.) This produces the clinical triad of atrophic, hyperlax, redundant ("cutis-laxa-like") skin.
7. Independently, disrupted TWIST2 function in hair-follicle-associated mesenchyme is associated with the striking congenital generalized hypertrichosis that clinically distinguishes BSS from its allelic neighbor AMS (which shares the eyelid/mouth phenotype but lacks prominent hypertrichosis). (Correlative/inferred — the precise mechanistic link between the E75Q/E75A substitution and follicular hair-cycle dysregulation, as opposed to the E75K/AMS substitution, has not been experimentally dissected in the sources found here; this is a genuine knowledge gap.)
8. Chronic ectropion/lagophthalmos secondary to the eyelid mesenchymal defect (step 5) leads, as a downstream secondary/acquired complication rather than a primary developmental defect, to chronic corneal exposure and exposure keratopathy, which is the principal driver of long-term ophthalmologic morbidity and surgical urgency. (Well-documented clinical complication, e.g., PMID:29329175, PMID:30455119.)

Supporting mechanistic detail by category

• Molecular pathway / transcription factor biology: TWIST2 is a class II bHLH transcription factor that binds E-box motifs (5′-CANNTG-3′) as a heterodimer with widely expressed bHLH partners (e.g., E12); it classically inhibits transcriptional activation driven by myogenic (MYOD1, MYOG) and osteogenic/MEF2-family (MEF2A, MEF2C) factors, and represses pro-inflammatory cytokine gene expression via inhibition of NF-κB-mediated transactivation (general TWIST2 biology, GeneCards/NCBI Gene summary, and PMID:26119818 background). GO terms of interest: GO:0000981 (DNA-binding transcription factor activity, RNA polymerase II-specific), GO:0046983 (protein dimerization activity), GO:0043433 (negative regulation of DNA-binding transcription factor activity), GO:0045892 (negative regulation of DNA-templated transcription).
• Cellular processes: Mesenchymal stem/progenitor cell differentiation is the central affected process — TWIST2 normally "mediates mesenchymal stem cell self-renewal by maintaining the immature phenotype and inhibiting osteogenesis and chondrogenesis" (search-derived synthesis of TWIST2 biology). Relevant GO biological process terms: GO:0030278 (regulation of ossification), GO:0045668 (negative regulation of osteoblast differentiation), GO:0060324 (face development), GO:0043010 (camera-type eye development)/eyelid-specific terms as available.
• Protein dysfunction: Altered/gained DNA-binding specificity of a bHLH basic-domain mutant, rather than classical misfolding or aggregation — a sequence-specificity switch mechanism (PMID:26119818).
• Tissue damage mechanisms: Skin — decreased elastic fiber content and hypocollagenosis (a developmental extracellular-matrix deficiency present from birth, not an acquired degenerative process) underlie the atrophic/redundant skin phenotype. Cornea — chronic mechanical exposure from ectropion/lagophthalmos (a biomechanical, not primary molecular, injury mechanism) underlies exposure keratopathy.
• Molecular/target-gene profiling: In the allelic Setleis syndrome (TWIST2 loss-of-function; see below), expression profiling of patient fibroblasts identified dysregulation of periostin (POSTN), an extracellular-matrix protein gene, among TWIST2 target genes ("Nonsense mutations of the bHLH transcription factor TWIST2 found in Setleis Syndrome patients cause dysregulation of periostin" — title/summary level only; the primary text could not be directly retrieved in this session due to a bot-check wall, so this should be treated as a lead to verify against the primary source, not a confirmed quote). A zebrafish model expressing mutant TWIST2 showed "severe head hypoplasia" and downregulation of extracellular matrix, membrane, and cytoskeleton gene categories (PMID:26119818), directly supporting the craniofacial-mesenchyme mechanism above.
• Single-cell / advanced omics: No single-cell, spatial transcriptomic, or multi-omic BSS-specific dataset was identified in this search — this is a clear gap consistent with the disease's extreme rarity.

Allelic mechanistic contrast (important for lump/split and mechanism curation)

The TWIST2 basic-domain locus at codon 75 shows a clean genotype-phenotype-mechanism correlation across three distinct disorders, useful for framing BSS's mechanism against its allelic neighbors:

This contrast is directly useful for the dismech mechanism module: it shows that the same gene, same protein domain produces a dominant gain-of-function/dominant-negative phenotype spectrum (AMS/BSS) when heterozygous missense, versus a recessive loss-of-function phenotype (Setleis) when biallelic null — a textbook illustration of the allelic-series concept, and a caution against treating "TWIST2-related disorder" as a single mechanism.

7. Anatomical Structures Affected

Organ level: - Primary: skin/integument (whole-body, most severe on back/trunk and forehead); periocular structures/eyelids; craniofacial skeleton and soft tissue (nose, mouth, ears); mammary tissue (hypoplasia); dentition. - Secondary/complication: cornea (exposure keratopathy secondary to eyelid dysfunction). - Body systems: integumentary system (primary), ophthalmologic/ocular adnexal system, craniofacial/musculoskeletal (mesenchymal patterning), reproductive/genitourinary (minority), auditory system (minority — conductive hearing loss), and, per some reports, mild central nervous system/developmental involvement in a minority of cases. - Suggested UBERON terms: UBERON:0002097 (skin of body), UBERON:0004085 (eyelid), UBERON:0000151 (nasal region), UBERON:0000202 (mouth region), UBERON:0001690 (ear), UBERON:0001911 (mammary gland).

Tissue and cell level: - Dermal fibroblasts and dermal connective tissue (atrophy, reduced elastic fiber and collagen content) — Cell Ontology CL:0000057 (fibroblast) / dermal fibroblast subtype if available. - Craniofacial mesenchyme / neural-crest-derived mesenchymal precursors — CL:0002092 (mesenchymal cell) or neural-crest-derived cell terms. - Hair follicle mesenchyme/dermal papilla (hypertrichosis) — CL:1001608-type dermal papilla terms if curating that level of detail. - Corneal epithelium (secondary exposure injury).

Subcellular level: Not a subcellular-pathology disease in the classical sense (no organelle-specific storage or trafficking defect reported); the core molecular lesion is nuclear — altered sequence-specific DNA binding of a transcription factor (GO Cellular Component: GO:0005634, nucleus; GO:0000785, chromatin).

Localization: - Skin findings are generalized/bilateral, with the back and forehead emphasized for hypertrichosis. - Facial/eyelid findings are essentially always bilateral and symmetric (bilateral ectropion, bilateral telecanthus) — no lateralization or asymmetry pattern was reported in this search.

8. Temporal Development

Onset: Congenital in essentially all reported features — the full facial gestalt, skin findings, hypertrichosis, and genital/nipple anomalies are present and recognizable at birth. No postnatal-onset primary features were identified.

Onset pattern: Not applicable in the acute/subacute/chronic sense used for acquired disease — this is a structural/developmental congenital malformation syndrome.

Progression: - The primary developmental phenotype (facial gestalt, skin texture, hypertrichosis) is generally stable/non-progressive after birth rather than degenerative, though the skin's aged/redundant appearance can create a superficial resemblance to a progressive progeroid process (see §6 differential). - The principal progressive element is secondary: chronic ectropion/lagophthalmos can lead to worsening corneal exposure, keratopathy, and potential visual compromise over time if uncorrected — this is the clearest example in BSS of a disease-stage trajectory (mild exposure → chronic keratopathy → risk of corneal scarring/vision loss), and the rationale for early and often repeated surgical intervention. - Growth retardation was noted in the original index case and some subsequent reports but is not universally emphasized as progressive.

Disease course pattern: Static congenital malformation with a superimposed chronic, potentially progressive ocular-surface complication; no remitting-relapsing pattern; lifelong condition (self-limited vs. chronic-lifelong: chronic lifelong, given permanence of the structural anomalies, though with normal life expectancy reported in most cases — no BSS-specific mortality data were found, and the disorder does not appear associated with reduced survival based on the case-report literature searched).

Critical periods: Neonatal/infant period is clinically critical for feeding support (macrostomia can complicate latch/feeding) and for early ophthalmologic assessment to prevent corneal complications; early childhood is the window for the major staged reconstructive surgical program (see §12).

9. Inheritance and Population

Epidemiology: Orphanet lists prevalence as <1/1,000,000, describing BSS as "a rare entity described in eleven patients to date" as of the Orphanet entry consulted; more recent case-report literature searched here suggests the total number of published probands has grown to roughly 15–25+ by the late 2010s (exact current total not independently re-tallied in this search — a precise current count should be obtained by a fresh literature search or GeneReviews-equivalent source at curation time rather than taken from this report as a fixed number). No incidence, national-registry, or GBD-level burden data exist for a disorder this rare.

Inheritance pattern: Autosomal dominant. Nearly all reported cases are simplex/de novo. Vertical (parent-to-child) transmission has been documented in at least two family reports and is explained mechanistically by parental mosaicism for the causative TWIST2 mutation rather than typical full heterozygosity in an overtly/typically-affected parent — i.e., recurrence in offspring of an apparently mildly affected or subtly affected parent reflects germline (and often somatic) mosaicism, not simple full penetrance with variable expressivity alone. (Note: some aggregator search snippets described BSS's inheritance as potentially "autosomal dominant or autosomal recessive" — this almost certainly reflects conflation with the separate, genuinely autosomal-recessive allelic disorder Setleis syndrome at the same locus, per §6, rather than a true AR form of BSS itself. Curators should not import an AR inheritance record for Barber-Say syndrome proper without independently verifying it against a primary source, as this looks like a database-level entity confusion rather than an established fact about BSS.)

Penetrance: Appears fully penetrant for the core facial/skin gestalt in every reported heterozygous carrier of a full (non-mosaic) E75Q/E75A mutation; formal penetrance estimates (e.g., from ClinGen) were not found in this search.

Expressivity: Variable — the mosaic-transmission family reports describe a mild-to-severe expressivity gradient tracking with mosaic vs. full germline mutation status (mosaic/mildly affected parent → severely affected, fully heterozygous child), and at least one report describes a distinctly milder BSS phenotype lacking ectropion (Pomili et al., PMID:9415700), indicating that even among fully heterozygous individuals there is a recognized phenotypic range.

Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).

Germline mosaicism: Directly documented and clinically important (see §2, §9 above) — PMID:26119818 and PMID:27092433 are the primary sources.

Founder effects: None reported; the causal mutations (E75Q, E75A) are recurrent-de-novo across genetically diverse, geographically dispersed families (reports span European, Indian, Japanese, and other populations in the literature retrieved), consistent with a mutational hotspot rather than a population-specific founder allele.

Consanguinity: Not a relevant risk factor for BSS itself (dominant, de novo); consanguinity is relevant for the allelic recessive disorder Setleis syndrome, where homozygous/compound-heterozygous null alleles require biparental transmission of a rare variant, and consanguineous families (e.g., the Mexican-Nahua sibship reported) are overrepresented in the Setleis literature — this should be kept clearly on the Setleis side of any dismech entry, not attributed to BSS.

Carrier frequency: Not applicable/not meaningful for a fully penetrant, essentially always-de-novo dominant disorder with no population carrier reservoir.

Population demographics: No specific ethnic or geographic enrichment was identified for BSS; reported cases span multiple continents/ethnicities. No sex-ratio skew was identified in this search (both male and female probands reported, including father-to-daughter and father-to-child transmissions). Age distribution at recognition is uniformly neonatal/early infancy, since the defining features are present at birth.

10. Diagnostics

Clinical recognition: BSS is primarily a clinical/gestalt diagnosis made at birth from the combination of congenital generalized hypertrichosis, atrophic/redundant ("cutis laxa-like") skin, bilateral ectropion, and macrostomia, supported by the accessory facial features (telecanthus, bulbous nose, dysplastic ears, low anterior hairline) — molecular confirmation is then sought.

Laboratory/genetic tests: - Single-gene TWIST2 sequence analysis (targeted Sanger or NGS sequencing of TWIST2 coding exons) is the definitive confirmatory test, given the strong genotype-phenotype correlation at a single recurrent codon; an NCBI GTR-listed clinical test specifically targets "TWIST2 gene (Sequence Analysis-All Coding Exons)" for Barber-Say syndrome (postnatal testing), confirming this is an established, commercially available single-gene test rather than requiring exome-first strategies in a clinically classic case. - Whole-exome/whole-genome sequencing is appropriate when the clinical gestalt is atypical or overlaps with AMS/other differentials, or in the diagnostic-odyssey setting before the phenotype is recognized as TWIST2-related — this is in fact how the causal gene was originally identified (Marchegiani et al. 2015 used exome and candidate-gene sequencing). - Chromosomal microarray/karyotype may be used to exclude a 2q37 deletion or other structural chromosomal cause in atypical presentations, given TWIST2's location within the 2q37 deletion-syndrome critical region, though this is a differential-exclusion step rather than the primary diagnostic route for classic BSS. - Skin biopsy/histopathology is a supportive (not gene-confirmatory) diagnostic tool, showing atrophic epidermis with mild orthohyperkeratosis, a thin reticular dermis, markedly decreased elastic fibers, and hypocollagenosis — a distinctive but non-specific pattern that supports the clinical diagnosis and helps distinguish BSS from other cutis-laxa-spectrum conditions on biopsy. - Ophthalmologic examination (slit-lamp, corneal surface assessment) is an essential diagnostic/monitoring test given the risk of exposure keratopathy, not for syndrome diagnosis per se but for morbidity surveillance. - Audiology is indicated given the minority occurrence of conductive hearing loss. - No BSS-specific circulating biomarker, imaging signature, or electrophysiologic test was identified.

Differential diagnosis (key entities to exclude/distinguish, per this search): - Ablepharon-macrostomia syndrome (AMS), OMIM #200110 — the closest allelic differential; distinguished by more severe/absent eyelids and lack of prominent hypertrichosis (see §6 table). Some authors argue AMS and BSS (and Setleis) may represent "a continuum" rather than fully distinct entities (PMID:19760652, "Case report supporting that the Barber-Say and ablepharon macrostomia syndromes could represent one disorder") — a lump/split consideration directly relevant to dismech's granularity guidance, since the molecular data (distinct, non-overlapping codon-75 substitutions with a clean genotype-phenotype split) currently support keeping them as distinct but closely related allelic entries rather than a single lumped disorder, while flagging the continuum argument in notes. - Setleis syndrome (FFDD3) — distinguished by autosomal recessive inheritance, homozygous/compound-het loss-of-function TWIST2 alleles, and a localized bitemporal scarring phenotype rather than the generalized skin/hypertrichosis pattern of BSS. - Progeroid/cutis laxa spectrum disorders — Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), congenital cutis laxa syndromes (including the arterial tortuosity/emphysema-associated recessive form), De Barsy syndrome (distinguished by corneal clouding and pseudoathetoid movements), Costello syndrome, and Ehlers-Danlos syndrome are cited generically in the differential-diagnosis literature for the "prematurely aged appearance + cutis laxa" phenotype cluster that BSS superficially resembles; none of these share the TWIST2 molecular basis. - Say-Barber-Biesecker-Young-Simpson syndrome (SBBYSS/KAT6B) — critically, not a true differential in the biological sense but a name-collision risk (see disambiguation section at top); should be explicitly excluded by clinicians/curators on the basis of gene (KAT6B, not TWIST2) and phenotype (blepharophimosis + severe developmental delay, not macrostomia/ectropion + typically normal cognition).

Screening: No population or newborn screening program exists or would be applicable (private, ultra-rare, non-metabolic single-gene disorder); prenatal diagnosis by targeted TWIST2 sequencing is possible in families with a known mutation (including at-risk mosaic-parent families), and detailed prenatal ultrasound might in principle detect macrostomia/facial anomalies, though no specific prenatal-ultrasound detection report was retrieved in this search.

11. Outcome/Prognosis

Survival/mortality: No BSS-specific survival statistics, life-expectancy figures, or mortality-rate data were identified in this search. The case-report literature does not describe BSS as a life-limiting condition; growth retardation has been noted in some cases, but reports emphasize surgical/reconstructive and ophthalmologic management rather than mortality risk. This should be recorded as an absence of evidence rather than evidence of normal survival — no formal natural-history or registry-based survival study exists for a disorder this rare.

Morbidity/function: The dominant morbidity is related to (a) chronic ocular surface disease from ectropion-driven exposure, with risk of keratopathy, corneal scarring, and potential vision impairment if uncorrected, and (b) the disfigurement and functional (feeding, speech, dental) impact of macrostomia and craniofacial anomalies, generally managed with staged reconstructive surgery. Cognitive/motor function is reported as normal in the majority of documented cases; a minority describe mild developmental delay, but this is not a defining or universal feature (again in contrast to SBBYSS/KAT6B, which is essentially always associated with significant developmental disability — a further reason the two names must not be conflated when recording prognosis).

Complications: Exposure keratopathy (most significant, potentially sight-threatening); feeding difficulty in infancy from macrostomia; dental crowding/malocclusion from macrostomia and delayed eruption; psychosocial impact of facial disfigurement; hearing impairment in a minority.

Recovery potential: With surgical intervention (staged eyelid reconstruction, oral commissuroplasty, orthognathic/rhinoplasty/genioplasty procedures as needed — see §12), functional and cosmetic outcomes are reported as favorable in the case literature, though repeated procedures over childhood are typical and the underlying tissue laxity/atrophy (a developmental connective-tissue deficiency, not merely a positional deformity) can complicate surgical durability.

Prognostic factors: Severity of ectropion (driving ocular risk) and macrostomia/craniofacial involvement are the main clinically tracked severity axes; whether a patient has a full heterozygous mutation versus arose from a mosaic-parent transmission has been suggested (in the mosaicism case reports) to correlate with phenotypic severity, but this has not been formalized into a validated prognostic scoring system.

Prognostic biomarkers: None identified.

12. Treatment

There is no disease-modifying or gene-targeted therapy for Barber-Say syndrome; management is entirely supportive and reconstructive/surgical, aimed at correcting the anatomic anomalies and preventing/treating secondary complications (chiefly corneal exposure).

Surgical/interventional (the primary treatment modality): - Staged eyelid reconstruction for ectropion/lagophthalmos — techniques reported include lateral tarsorrhaphy, full-thickness skin grafting (donor sites reported: volar forearm, retroauricular area, supraclavicular fossa), and autologous fat (lipo)grafting for periorbital volume restoration (multidisciplinary case report, PMID:30455119, "Multidisciplinary eyelid reconstruction in Barber-Say syndrome"). Suggested NCIT term: NCIT:C15329 (Surgical Procedure), or a more specific oculoplastic reconstruction term if the KB's NCIT mapping supports it. - Mid-face lift and eyelid repositioning, sometimes combined with botulinum toxin adjunct treatment, reported for symptomatic corneal exposure management in an adult BSS patient, with resolution of signs/symptoms of exposure keratopathy. - Macrostomia correction (commissuroplasty/cheiloplasty) — lip/oral commissure reconstruction to narrow the mouth. NCIT: a specific cheiloplasty/reconstructive oral surgery term. - Orthognathic surgery for jaw correction, rhinoplasty for nasal reconstruction, genioplasty for chin correction, and malar (cheek) implants for facial contour — reported as part of the broader staged craniofacial reconstructive program in one comprehensive surgical case series retrieved in this search. - Anesthetic management considerations are themselves a documented topic in the literature — a case report specifically addresses "General anesthesia of a Japanese infant with Barber-Say syndrome," presumably reflecting airway/feeding-related considerations relevant to macrostomia and craniofacial anatomy (specific anesthetic findings were not independently extracted in this search and should be pulled directly from that source if curating perioperative-risk content).

Supportive/rehabilitative care: - Ophthalmologic surveillance and lubrication/ocular surface protection (artificial tears, ointments, protective measures against exposure) as first-line, non-surgical management of ectropion-related dryness, presumably standard-of-care though not separately quoted from a specific source in this search — this should be verified against a primary ophthalmology reference before being cited as an evidence-backed BSS-specific recommendation rather than general exposure-keratopathy management extrapolated to this condition. - Feeding support in infancy given macrostomia. - Dental/orthodontic management for delayed eruption, malocclusion, and gingival overgrowth. - Audiology follow-up and hearing support where conductive hearing loss is present. - Genetic counseling (NCIT:C15240) is clearly indicated given the demonstrated risk of parental germline mosaicism affecting recurrence-risk counseling, distinct from the low recurrence risk that would be quoted for a purely simplex de novo dominant disorder.

Pharmacotherapy: No BSS-specific pharmacologic treatment exists; botulinum toxin is used adjunctively for periocular/eyelid positioning in at least one reported case (see above) rather than as disease treatment per se.

Experimental/advanced therapeutics: None — no gene therapy, cell therapy, or targeted molecular therapy has been reported or is currently applicable given the transcription-factor, developmental-malformation nature of the disease; no active ClinicalTrials.gov or WHO ICTRP trial was identified for Barber-Say syndrome in this search (consistent with its extreme rarity and the absence of a modifiable downstream pathway analogous to, e.g., an enzyme-replacement target).

Treatment strategy: Management follows a staged, multidisciplinary reconstructive algorithm beginning in infancy (ophthalmologic protection, feeding support) and continuing through childhood/adolescence with sequential craniofacial and periocular surgeries, coordinated across ophthalmology/oculoplastics, craniofacial/plastic surgery, dentistry/orthodontics, audiology, and clinical genetics — rather than a single-specialty or drug-based algorithm.

13. Prevention

Primary prevention: Not applicable in the population sense — BSS arises from de novo or mosaic-transmitted dominant mutation and has no modifiable environmental risk factor to intervene on.

Secondary prevention: Early neonatal ophthalmologic assessment and initiation of ocular-surface protection is the key secondary-prevention measure, aimed at forestalling progression to corneal scarring/vision loss from chronic exposure keratopathy — this is the clearest tertiary/secondary-prevention opportunity documented in the literature reviewed.

Genetic counseling/reproductive prevention: For families with a previously affected child (especially where a parent shows even mild/subtle features suggestive of mosaicism), prenatal or preimplantation genetic testing using the known familial TWIST2 mutation is the applicable reproductive risk-reduction strategy, directly motivated by the documented germline mosaicism transmission cases (PMID:26119818, PMID:27092433). Recurrence risk counseling should explicitly account for the possibility of parental mosaicism rather than assuming a negligible recurrence risk purely because both parents appear clinically unaffected.

Screening: No population, newborn, or carrier screening program is applicable, as discussed in §10.

Public health/behavioral/immunization/prophylaxis: Not applicable to this disorder.

14. Other Species / Natural Disease

No naturally occurring TWIST2-related disease analogous to Barber-Say syndrome was identified in other species in this search (no OMIA entry, veterinary case series, or companion-animal report was found). This appears to be a human-specific clinical entity in the literature surveyed, though this absence should be read as "not found in this search" rather than a confirmed negative — a dedicated OMIA search was not exhaustively performed here.

Orthologous gene: Twist2 is highly conserved; the mouse ortholog is Twist2 (MGI:104685, "twist basic helix-loop-helix transcription factor 2"), and zebrafish possess a twist2/dermo1 ortholog used experimentally (see below and §6). No natural/spontaneous disease-causing Twist2 variant has been reported in these model species outside of engineered/knockout research models.

Comparative biology: TWIST2's role in inhibiting mesenchymal (myogenic/osteogenic) differentiation and in dermal fibroblast/scale development is evolutionarily conserved from fish to mammals — e.g., zebrafish twist2/dermo1 "regulates scale shape and scale organization during skin development and regeneration" (search-identified ScienceDirect source), a functional parallel to its role in mammalian dermal development, though scales are not a direct model for human skin pathology.

15. Model Organisms

Mouse (Mus musculus): - Twist2-null (knockout) mice are the best-characterized mammalian model of TWIST2 loss-of-function, though they model a phenotype closer to the biology relevant to the recessive Setleis end of the allelic spectrum (complete loss of function) rather than the dominant-negative/gain-of-function BSS mutations. Reported phenotype: "The Twist2-KO mouse presents relatively normal embryonic development and no notable bone abnormalities, but typically dies 2–3 days after birth due to cachexia, failure to thrive and high levels of pro-inflammatory cytokines," with the mechanism attributed to loss of TWIST2's normal repression of NF-κB-driven pro-inflammatory cytokine expression across multiple tissues, producing apoptosis, cachexia, and neonatal lethality, described as resembling TNFα-induced cachexia models. This is an important model-fidelity caveat for dismech curation: the null mouse's dominant, life-limiting phenotype (neonatal lethal systemic cytokine-driven cachexia) is not the human BSS phenotype (a viable, non-lethal craniofacial/dermal malformation syndrome) — consistent with the human disease being caused by a dominant dual dominant-negative/gain-of-function missense mechanism rather than simple biallelic loss of function, and any AnimalModel.modeled_mechanisms link from a Twist2-null mouse to a BSS pathophysiology node should likely be PARTIALLY_RECAPITULATES or FAILS_TO_RECAPITULATE at best, with explicit limitations describing this genotype mismatch (null vs. dominant-negative/gain-of-function missense) rather than RECAPITULATES. - No knock-in mouse model carrying the human BSS-specific p.Glu75Gln or p.Glu75Ala substitution was identified in this search — this appears to be a genuine gap in the literature (an E75K/E75Q/E75A knock-in mouse, which would far more faithfully model the dominant human mutation mechanism, does not appear to have been published as of the sources retrieved here). This is an explicit, actionable knowledge gap worth flagging in a HUMAN_MODEL_MISMATCH discussion if this entry is curated in dismech.

Zebrafish (Danio rerio): - Used directly in the pivotal Marchegiani et al. 2015 study to functionally test the human BSS/AMS mutant TWIST2 proteins: expression of mutant TWIST2 produced "severe head hypoplasia" and downregulation of extracellular-matrix, membrane, and cytoskeleton gene expression programs — this is the most disease-relevant model system identified for the dominant-negative/gain-of-function mechanism specifically, since it used the actual human disease-causing substitutions rather than a null allele, and directly supports the craniofacial-mesenchyme step of the causal chain in §6. - Separately, wild-type zebrafish twist2/dermo1 has been used as a normal-development model for dermal/scale formation, informing general TWIST2 developmental biology rather than disease modeling per se.

Cell-based/in vitro models: - HeLa cell transfection with Flag-tagged wild-type and mutant TWIST2 constructs, used for the ChIP-seq/DNA-binding-pattern comparison described in §6 (PMID:26119818) — an in vitro molecular model of the mechanistic lesion, not a tissue/organismal disease model. - Patient-derived fibroblasts have been used in the allelic Setleis syndrome literature for expression profiling of TWIST2 target genes (including the periostin/POSTN finding noted in §6) — no equivalent BSS (dominant-negative/gain-of-function allele) patient-fibroblast transcriptomic study was identified in this search, representing a further gap: the mechanistic downstream-target data that exists is largely from the loss-of-function (Setleis) side of the allelic series, not from BSS's own gain-of-function/dominant-negative alleles.

Model limitations, summarized: No model organism currently available (null mouse, zebrafish mutant-TWIST2 embryo, or in vitro assay) fully recapitulates the complete human BSS phenotype (combined hypertrichosis + cutis-laxa-like skin + ectropion + macrostomia + normal viability/typically normal cognition) in a single system; the null mouse models a different (lethal, cytokine-driven) end of the TWIST2 loss-of-function spectrum, and the zebrafish data — while using the correct disease-causing mutation — captures gross craniofacial hypoplasia and gene-expression changes rather than the specific eyelid/dermal/hair-follicle phenotypes that define the human clinical picture.

Summary of Key Citations

Explicit gaps and caveats for curation

1. OMIM full-text access failed (HTTP 403) during this research session; the OMIM-attributed statements above come from search-engine-indexed excerpts of the OMIM entry/clinical synopsis, not a direct read of the primary source, and should be re-fetched and re-verified before being cited as OMIM content in a KB entry.
2. The periostin/POSTN target-gene finding is reported here at title/abstract-summary level only (PMC7922891 could not be fetched past a bot-check page); treat as an unverified lead, not a quotable finding, and it concerns Setleis syndrome (loss-of-function) fibroblasts, not BSS's dominant-negative/gain-of-function alleles specifically.
3. The apparent "autosomal recessive" inheritance tag for BSS surfaced in one aggregator search result and is very likely a database-level conflation with the genuinely recessive allelic disorder Setleis syndrome; do not curate BSS itself as having AR inheritance without independent primary-source verification.
4. No current, precise total case count was obtained (most specific figures found ranged from "11" (Orphanet, pre-2015) to "~15" (2017) to "<20" (2019); a fresh count was not independently performed here).
5. No GeneReviews chapter and no formal natural-history, registry, or QOL-instrument study exist for this condition — all clinical-course, prognosis, and QOL content in this report is aggregated from individual case reports, which should be reflected in evidence grading (individual human clinical case-report evidence, not cohort-level).
6. No knock-in mouse model of the human BSS mutation was found — an explicit, worth-flagging translational gap between the available Twist2-null mouse (a different, lethal loss-of-function phenotype) and the human dominant-negative/gain-of-function disease.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

• PMID:26119818: "The mutations are located in the basic domain of the protein, and molecular analyses suggested that the mutations alter the DNA-binding activity of TWIST2, leading to both dominant-negative and gain-of-function effects"
• closest text in source: "Molecular analyses suggest that these mutations alter the DNA-binding activity of TWIST2, leading to both dominant-negative and gain-of-function effects"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0000656 (1 mention) - the report calls it "Ectropion (bilateral, of both upper and lower eyelids)"; HP calls it Ectropion
• UBERON:0004085 (1 mention) - the report calls it "eyelid"; UBERON calls it labium majora
• UBERON:0000151 (1 mention) - the report calls it "nasal region"; UBERON calls it pectoral fin
• UBERON:0000202 (1 mention) - the report calls it "mouth region"; UBERON calls it glial blood brain barrier

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• HP:0007756 (obsolete Slitlike anterior chamber angles in children) (1 mention) - replaced by HP:0000594
• GO:0043433 (obsolete negative regulation of DNA-binding transcription factor activity) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000154 (1 mention) - the report calls it "Macrostomia (wide mouth)"; HP calls it Wide mouth
• HP:0001263 (1 mention) - the report calls it "Mild psychomotor/developmental delay"; HP calls it Global developmental delay, and lists "Psychomotor developmental delay" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.